Photodiagnosis and Photodynamic Therapy
Volume 6, Issue 2 , Pages 97-104, June 2009

Pharmacokinetics and biodistribution of Photolon® (Fotolon®) in intact and tumor-bearing rats

  • S.V. Shliakhtsin, MSc

      Affiliations

    • RUE “Belmedpreparaty”, 220007 Minsk, Fabritsiusa str. 30, Belarus
    • Tel.: +375 17 220 39 40; fax: +375 17 220 39 40.
    • Corresponding Author InformationCorresponding author at: Department of Pharmacology and Toxicology of RUE “Belmedpreparaty”, 220007 Minsk, Fabritsiusa str. 30, Belarus. Tel.: +375 17 220 39 40; fax: +375 17 220 31 42.
    • ,
  • T.V. Trukhachova

      Affiliations

    • RUE “Belmedpreparaty”, 220007 Minsk, Fabritsiusa str. 30, Belarus
    • Tel.: +375 17 220 31 42; fax: +375 17 220 31 42.
    • ,
  • H.A. Isakau

      Affiliations

    • RUE “Belmedpreparaty”, 220007 Minsk, Fabritsiusa str. 30, Belarus
    • Tel.: +375 17 220 39 40; fax: +375 17 220 39 40.
    • ,
  • Y.P. Istomin

      Affiliations

    • N.N. Alexandrov National Cancer Centre of Belarus, 223040 Minsk, p.o. Lesnoy-2, Belarus
    • Tel: +375 17 220 39 40.

published online 22 June 2009.

Summary 

Background

This paper provides the results of the non-clinical evaluation of biodistribution of the PS Photolon® in inner organs and tissues of intact and tumor-bearing rats with xenograft tumors of different morphologic types.

Methods

The accumulation studies were performed in rats by means of intravital laser fluorimetry in situ and spectrophotometric determination ex vivo.

Results

The biodistribution pattern of Photolon® does not depend on tumor carriage as well as on morphologic type of the xenograft tumor. We have also showed that Photolon® easily crosses an intact blood–brain barrier and accumulates in tissues of central nervous system. The relative bioavailability of brain tissues for Photolon® was estimated as 82%, Tmax—30min, mean residual time (MRT)—1.6h.

Conclusions

In general, results of the experimental study of biodistribution of Photolon® in inner organs and tissues of rats, performed as in real time (by means of intravital laser fluorimetry in situ) as ex vivo (spectrophotometric assay) can be utilized while optimizing existing regimens of PDT with the purpose to increase safety and efficacy of treatment as well as for the development of new PDT protocols with Photolon® applied for new indications. Parameters of pharmacokinetics and biodistribution of Photolon®/Fotolon® as well as its’ ability to cross an intact blood–brain barrier, are optimal for the majority of modern clinical applications of PDT.

Keywords: Photolon®, Biodistribution, Blood–brain barrier, Pharmacokinetics

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1572-1000(09)00034-9

doi:10.1016/j.pdpdt.2009.04.002

Photodiagnosis and Photodynamic Therapy
Volume 6, Issue 2 , Pages 97-104, June 2009

Article Tools

* Image Usage & Resolution